- World rank, all time
- #41,957 of 42,892
- Rank in Brazil
- #843 of 870
- Research works
- 154 ▲ 96% vs 2013–17
- Citations
- 1.7k 10.9 per fractional work
- Top-10% rate
- 2.6% record average 16.5%
- Open access
- 58% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Medicine, 4.1×. Every wedge is a field page.
- Medicine 4.1×
- Biochemistry, Genetics and Molecular Biology 1.8×
- Immunology and Microbiology 1.0×
- Dentistry 1.0×
- Nursing 0.4×
- Economics, Econometrics and Finance 0.4×
- Computer Science 0.4×
- Agricultural and Biological Sciences 0.3×
- Neuroscience 0.3×
- Social Sciences 0.2×
- Business, Management and Accounting 0.2×
- Engineering 0.1×
- Psychology 0.1×
- Mathematics 0.1×
- Environmental Science 0.0×
Who are the top researchers at Instituto Brasileiro de Controle do Câncer?
Ranked on the composite score, Felipe Melo Cruz and André Lopes lead among researchers whose main affiliation is Instituto Brasileiro de Controle do Câncer.
- 1 Felipe Melo Cruz Brazil · #198,417 worldwide 131 citations · 21 works
- 2 André Lopes Brazil · #1,282,145 worldwide 3 citations · 27 works
Which keywords describe research at Instituto Brasileiro de Controle do Câncer?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Chemotherapy, Quality of Life, Radiotherapy, Complications, Clinical Trials, Breast Cancer, Breast Reconstruction and Metastasis.
- Empirical Studies
- Agile Software Development
- Febrile Neutropenia
- Antimicrobial Agents
- Molecular Profiling
- Breast Tumours
- Gene Expression
- Microsurgical Reconstruction
- Prophylaxis
- Patient-Reported Outcome Measure
- Acellular Dermal Matrix
- Survival Analysis
- Cytoreductive Surgery
- Prognostic Factors
- Clinical Practice Guidelines
- Ovarian Cancer
- Metastasis
- Breast Cancer
- Complications
- Quality of Life
- Chemotherapy
- Radiotherapy
- Clinical Trials
- Breast Reconstruction
- Epidemiology
- Biomarkers
- Immunotherapy
- Genomic Analysis
- Mutation Analysis
- Tumor Models
- Guidelines
- Prognostic Markers
- Free Flap
- Neoadjuvant Therapy
- Targeted Therapy
- Immunohistochemistry
- Treatment Response
- Cervical Cancer
- Metastatic Breast Cancer
- Anatomy
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Chemotherapy6▲ 21×16 topics
- Quality of Life4▲ 7.9×10 topics
- Radiotherapy4▲ 25×9 topics
- Complications3▲ 18×4 topics
- Clinical Trials3▲ 12×8 topics
- Breast Cancer3▲ 33×8 topics
- Breast Reconstruction3▲ 123×2 topics
- Metastasis3▲ 21×3 topics
- Epidemiology2▲ 1.58×12 topics
- Ovarian Cancer2▲ 70×2 topics
- Biomarkers2▲ 8.7×3 topics
- Clinical Practice Guidelines2▲ 11×7 topics
- Immunotherapy2▲ 7.5×8 topics
- Prognostic Factors2▲ 12×10 topics
- Genomic Analysis2▲ 20×2 topics
- Cytoreductive Surgery2▲ 68×2 topics
- Mutation Analysis2▲ 58×1 topic
- Survival Analysis2▲ 16×5 topics
- Tumor Models2▲ 73×1 topic
- Acellular Dermal Matrix2▲ 191×1 topic
- Guidelines2▲ 8.2×3 topics
- Patient-Reported Outcome Measure2▲ 191×1 topic
- Prognostic Markers2▲ 36×2 topics
- Prophylaxis2▲ 29×2 topics
- Free Flap1▲ 89×1 topic
- Microsurgical Reconstruction1▲ 89×1 topic
- Neoadjuvant Therapy1▲ 15×4 topics
- Gene Expression1▲ 5.6×2 topics
- Targeted Therapy1▲ 15×4 topics
- Breast Tumours1▲ 65×1 topic
- Immunohistochemistry1▲ 41×3 topics
- Molecular Profiling1▲ 31×3 topics
- Treatment Response1▲ 65×1 topic
- Antimicrobial Agents1▲ 179×1 topic
- Cervical Cancer1▲ 27×3 topics
- Febrile Neutropenia1▲ 179×1 topic
- Metastatic Breast Cancer1▲ 48×2 topics
- Agile Software Development1▲ 109×1 topic
- Anatomy1▲ 37×2 topics
- Empirical Studies1▲ 109×1 topic
Which research topics does Instituto Brasileiro de Controle do Câncer publish most on?
By volume in 2022–2025: Ovarian cancer diagnosis and treatment, Breast Implant and Reconstruction, Reconstructive Surgery and Microvascular Techniques and Breast Cancer Treatment Studies.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Ovarian cancer diagnosis and treatment Reproductive Medicine 2 works
- 2 Breast Implant and Reconstruction Surgery 2 works
- 3 Reconstructive Surgery and Microvascular Techniques Surgery 1 works
- 4 Breast Cancer Treatment Studies Cancer Research 1 works
- 5 Neutropenia and Cancer Infections Oncology 1 works
- 6 Software Engineering Techniques and Practices Information Systems 1 works
- 7 Education and Digital Technologies Sociology and Political Science 1 works
- 8 Cancer Treatment and Pharmacology Oncology 1 works
- 9 Cardiac, Anesthesia and Surgical Outcomes Cardiology and Cardiovascular Medicine 1 works
- 10 Reconstructive Facial Surgery Techniques Surgery 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Instituto Brasileiro de Controle do Câncer's research output changed?
Output in 2018–2022 was 96% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in São Paulo
- Universidade de São Paulo
- Universidade Estadual Paulista (Unesp)
- Universidade Federal de São Paulo
- Pontifícia Universidade Católica de São Paulo
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
- Hospital Universitário da Universidade de São Paulo
- Universidade Brasil
- Universidade Presbiteriana Mackenzie
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.